Investigational non-hormonal oral male contraceptive in Phase 2 clinical trials that suppresses sperm production by blocking retinoic acid receptor-alpha.
YCT-529 is an oral, non-hormonal drug candidate from YourChoice Therapeutics that selectively antagonizes retinoic acid receptor-alpha (RAR-alpha) to suppress sperm production. Preclinical studies showed the effect reverses after stopping treatment. The compound is currently in Phase 2 clinical trials evaluating safety, tolerability, and pharmacokinetics and has not been approved by any regulatory authority. YCT-529 is a product of YourChoice Therapeutics.